Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Phage-Polymer Nanoparticles for Treatment of Antibiotic-Recalcitrant Wound Biofilm Infections

Award Number: R01AI186027
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/06/2025
PERIOD OF PERFORMANCE END DATE: 05/31/2030

Group Awards By:

View Award Description

Phage-Polymer Nanoparticles for Treatment of Antibiotic-Recalcitrant Wound Biofilm Infections - Project Summary Phage-Polymer Nanoparticles for Treatment of Antibiotic-Recalcitrant Wound Biofilm Infections Wound biofilm infections are associated with significant morbidity, mortality, and cost, and can be refractory to conventional antibiotic treatment. The proposed research will create new polymer-phage conjugates to treat wound infections. Phage therapy provides a self-amplifying strategy to combat bacterial infections. However, phages do not efficiently penetrate into the dense biofilm matrix, limiting the efficacy of phage therapies for treating biofilm infections. These issues will be addressed through integration of nanomaterials developed by Rotello with the in vitro, in vivo, and clinical expertise of Patel in phage therapy. In published studies, Rotello and Patel demonstrated that engineered polymers can encapsulate phages to generate non-covalent protein-phage nanoparticles (PPNs) that retain infectivity and feature enhanced efficacy against biofilms relative to free phage in vitro and in vivo. In the proposed research, Rotello will develop new homopolymers and block copolymers to generate polymer-phage conjugates, focusing on Phage K that Patel has shown has cross-strain and cross-species activity. These polymers will use a cationic block to electrostatically anchor the polymer to phages. One PPN family will systematically vary the hydrophobicity of the homopolymer to optimize biofilm penetration and eradication. The second PPN polymer will feature an exterior block with charge-switchable functionality that will go from anionic (non-interacting) to cationic (biofilm penetrating) at biofilm pH, providing targeted delivery of PPN. Conjugates will be screened in vitro against methicillin-resistant Staphylococcus aureus (MRSA) planktonic bacteria and biofilms. Effective PPNs will be incorporated into hydrogels, with hydrogel porosity used to provide controlled PPN delivery. Conjugates effective in vitro will be screened in a realistic murine wound biofilm by Rotello. Patel will then perform pre-clinical studies of the antimicrobial and wound healing efficacy of PPNs, supported by histopathology. Aim 1: Rotello will synthesize homo- and block copolymers and non-covalently conjugate them to phages specific against MRSA study isolates. Infectivity of the conjugates will be quantified and will be tested for biofilm penetration and eradication. Patel will establish cross-strain and cross-species activities of phages. Aim 2. Rotello will incorporate effective PPNs into hydrogels to provide wound dressings with controlled release of phage. Our expectation is that control of hydrogel pore size will regulate PPN release, providing optimal phage activity. Aim 3. Rotello and Patel will use murine wound biofilm models to test PPN-hydrogel wound dressings. These studies will combine parametric pilot experiments using luminescent MRSA by Rotello with full pre-clinical evaluation by Patel. Efficacy in these models will be quantified by decreased bacterial counts, enhanced wound healing, diminished purulence, and decreased inflammation as outcomes.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $554,262 )
2026	2026	UNIVERSITY OF MASSACHUSETTS	101 COMMONWEALTH AVE	AMHERST	MA	01003	HAMPSHIRE	USA	Allergy and Infectious Diseases Research	000	2	5/1/2026	NON-COMPETING CONTINUATION	$554,262
														Subtotal = $554,262

Issue Date FY: 2025 ( Subtotal = $593,860 )
2025	2025	UNIVERSITY OF MASSACHUSETTS	101 COMMONWEALTH AVE	AMHERST	MA	01003	HAMPSHIRE	USA	Allergy and Infectious Diseases Research	000	1	6/6/2025	NEW	$593,860
														Subtotal = $593,860

Grand Total All Awards = $1,148,122

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Phage-Polymer Nanoparticles for Treatment of Antibiotic-Recalcitrant Wound Biofilm Infections

Award Number: R01AI186027

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/06/2025

PERIOD OF PERFORMANCE END DATE: 05/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer